


## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3857639/publications.pdf Version: 2024-02-01



VI CUI

#	Article	IF	CITATIONS
1	Emerging HxNy Influenza A Viruses. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a038406.	6.2	30
2	Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients. Human Immunology, 2022, 83, 119-129.	2.4	17
3	Legionella pneumophila Risk from Cooling Tower Systems in China. Applied and Environmental Microbiology, 2022, 88, AEM0192121.	3.1	3
4	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nature Microbiology, 2022, 7, 423-433.	13.3	78
5	Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity. Emerging Microbes and Infections, 2022, 11, 1024-1036.	6.5	5
6	Comparative study on virus shedding patterns in nasopharyngeal and fecal specimens of COVID-19 patients. Science China Life Sciences, 2021, 64, 486-488.	4.9	95
7	ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation. Developmental Cell, 2021, 56, 427-442.e5.	7.0	250
8	A broadly protective antibody that targets the flavivirus NS1 protein. Science, 2021, 371, 190-194.	12.6	66
9	Downregulated miR-451a as a feature of the plasma cfRNA landscape reveals regulatory networks of IL-6/IL-6R-associated cytokine storms in COVID-19 patients. Cellular and Molecular Immunology, 2021, 18, 1064-1066.	10.5	31
10	Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir. Innovation(China), 2021, 2, 100080.	9.1	51
11	Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. Signal Transduction and Targeted Therapy, 2021, 6, 51.	17.1	20
12	SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell, 2021, 184, 2362-2371.e9.	28.9	332
13	Avian influenza A (H7N9) virus: from low pathogenic to highly pathogenic. Frontiers of Medicine, 2021, 15, 507-527.	3.4	30
14	Identification of antibiotic resistance genes and associated mobile genetic elements in permafrost. Science China Life Sciences, 2021, 64, 2210-2213.	4.9	5
15	<i>Mycobacterium tuberculosis</i> protein kinase G acts as an unusual ubiquitinating enzyme to impair host immunity. EMBO Reports, 2021, 22, e52175.	4.5	23
16	Cryo-EM structures of Lassa and Machupo virus polymerases complexed with cognate regulatory Z proteins identify targets for antivirals. Nature Microbiology, 2021, 6, 921-931.	13.3	20
17	Current knowledge of COVID-19: Advances, challenges and future perspectives. Biosafety and Health, 2021, 3, 202-209.	2.7	4
18	Tracing the origins of SARS-CoV-2: lessons learned from the past. Cell Research, 2021, 31, 1139-1141.	12.0	25

#	Article	IF	CITATIONS
19	Integrated gut virome and bacteriome dynamics in COVID-19 patients. Gut Microbes, 2021, 13, 1-21.	9.8	81
20	Meclizine Inhibits Pseudorabies Virus Replication by Interfering With Virus Entry and Release. Frontiers in Microbiology, 2021, 12, 795593.	3.5	4
21	Structures of the fourÂlg-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex. Cellular and Molecular Immunology, 2020, 17, 966-975.	10.5	38
22	Inference of person-to-person transmission of COVID-19 reveals hidden super-spreading events during the early outbreak phase. Nature Communications, 2020, 11, 5006.	12.8	80
23	Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients. Immunity, 2020, 53, 685-696.e3.	14.3	299
24	Dominant subtype switch in avian influenza viruses during 2016–2019 in China. Nature Communications, 2020, 11, 5909.	12.8	93
25	The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro. Signal Transduction and Targeted Therapy, 2020, 5, 275.	17.1	40
26	Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus. MBio, 2020, 11, .	4.1	12
27	Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nature Communications, 2020, 11, 4417.	12.8	394
28	Cryo-EM structure of the varicella-zoster virus A-capsid. Nature Communications, 2020, 11, 4795.	12.8	10
29	Diversity and abundance of resistome in rhizosphere soil. Science China Life Sciences, 2020, 63, 1946-1949.	4.9	1
30	Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2. Cell Reports, 2020, 31, 107774.	6.4	216
31	Structural insight into arenavirus replication machinery. Nature, 2020, 579, 615-619.	27.8	51
32	New Virus, New Challenge. Innovation(China), 2020, 1, 100005.	9.1	9
33	A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro. PLoS Computational Biology, 2020, 16, e1008489.	3.2	42
34	The Genome Resequencing of TCR Loci in <i>Gallus gallus</i> Revealed Their Distinct Evolutionary Features in Avians. ImmunoHorizons, 2020, 4, 33-46.	1.8	10
35	Title is missing!. , 2020, 16, e1008489.		0
36	Title is missing!. , 2020, 16, e1008489.		0

#	Article	IF	CITATIONS
37	Title is missing!. , 2020, 16, e1008489.		Ο
38	Title is missing!. , 2020, 16, e1008489.		0
39	Structural insight into multistage inhibition of CRISPR-Cas12a by AcrVA4. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 18928-18936.	7.1	21
40	Azithromycin Protects against Zika Virus Infection by Upregulating Virus-Induced Type I and III Interferon Responses. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	83
41	Structural insight into RNA synthesis by influenza D polymerase. Nature Microbiology, 2019, 4, 1750-1759.	13.3	58
42	Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development. Cancer Immunology Research, 2019, 7, 1244-1257.	3.4	51
43	Salt bridge-forming residues positioned over viral peptides presented by MHC class I impacts T-cell recognition in a binding-dependent manner. Molecular Immunology, 2019, 112, 274-282.	2.2	5
44	Discs large homolog 1 regulates B-cell proliferation and antibody production. International Immunology, 2019, 31, 759-770.	4.0	2
45	Human Neonatal Fc Receptor Is the Cellular Uncoating Receptor for Enterovirus B. Cell, 2019, 177, 1553-1565.e16.	28.9	69
46	Light chain modulates heavy chain conformation to change protection profile of monoclonal antibodies against influenza A viruses. Cell Discovery, 2019, 5, 21.	6.7	15
47	Antibiotic resistance gene reservoir in live poultry markets. Journal of Infection, 2019, 78, 445-453.	3.3	40
48	Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. Nature Microbiology, 2019, 4, 1231-1241.	13.3	39
49	Avian-to-Human Receptor-Binding Adaptation of Avian H7N9 Influenza Virus Hemagglutinin. Cell Reports, 2019, 29, 2217-2228.e5.	6.4	27
50	Intact Glycopeptide Analysis of Influenza A/H1N1/09 Neuraminidase Revealing the Effects of Host and Glycosite Location on Siteâ€6pecific Glycan Structures. Proteomics, 2019, 19, 1800202.	2.2	5
51	Third Tofo Advanced Study Week on Emerging and Re-emerging Viruses, 2018. Antiviral Research, 2019, 162, 142-150.	4.1	3
52	Structure–function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans. Nature Microbiology, 2019, 4, 306-315.	13.3	41
53	Double Lock of a Human Neutralizing and Protective Monoclonal Antibody Targeting the Yellow Fever Virus Envelope. Cell Reports, 2019, 26, 438-446.e5.	6.4	49
54	Mycobacterium tuberculosis Mce2E suppresses the macrophage innate immune response and promotes epithelial cell proliferation. Cellular and Molecular Immunology, 2019, 16, 380-391.	10.5	32

#	Article	IF	CITATIONS
55	Crystal Structure of the Capsid Protein from Zika Virus. Journal of Molecular Biology, 2018, 430, 948-962.	4.2	98
56	The S190R mutation in the hemagglutinin protein of pandemic H1N1 2009 influenza virus increased its pathogenicity in mice. Science China Life Sciences, 2018, 61, 836-843.	4.9	3
57	Novel cyclo-peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein. Antiviral Research, 2018, 155, 1-11.	4.1	18
58	The virulence of <i>Legionella pneumophila</i> is positively correlated with its ability to stimulate NF-κB activation. Future Microbiology, 2018, 13, 1247-1259.	2.0	5
59	An autoimmune disease variant of IgG1 modulates B cell activation and differentiation. Science, 2018, 362, 700-705.	12.6	28
60	Structures of Zika Virus E & NS1: Relations with Virus Infection and Host Immune Responses. Advances in Experimental Medicine and Biology, 2018, 1062, 77-87.	1.6	13
61	An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques. Emerging Microbes and Infections, 2018, 7, 1-12.	6.5	16
62	Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium. Scientific Reports, 2017, 7, 41226.	3.3	41
63	An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nature Communications, 2017, 8, 14369.	12.8	192
64	The crystal structure of Zika virus <scp>NS</scp> 5 reveals conserved drug targets. EMBO Journal, 2017, 36, 919-933.	7.8	107
65	Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nature Communications, 2017, 8, 15092.	12.8	649
66	Conserved Vδ1 Binding Geometry in a Setting of Locus-Disparate pHLA Recognition by δ/αβ T Cell Receptors (TCRs): Insight into Recognition of HIV Peptides by TCRs. Journal of Virology, 2017, 91, .	3.4	15
67	Alternate binding modes of anti-CRISPR viral suppressors AcrF1/2 to Csy surveillance complex revealed by cryo-EM structures. Cell Research, 2017, 27, 853-864.	12.0	64
68	Structural Biology of the Zika Virus. Trends in Biochemical Sciences, 2017, 42, 443-456.	7.5	98
69	Structures of human-infecting <i>Thogotovirus</i> fusogens support a common ancestor with insect baculovirus. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8905-E8912.	7.1	29
70	Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7564-E7573.	7.1	98
71	Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Research, 2017, 27, 151-153.	12.0	116
72	Pediatric Drug Nitazoxanide: A Potential Choice for Control of Zika. Open Forum Infectious Diseases, 2017, 4, ofx009.	0.9	35

#	Article	IF	CITATIONS
73	Crystal structure of the C-terminal fragment of NS1 protein from yellow fever virus. Science China Life Sciences, 2017, 60, 1403-1406.	4.9	11
74	CASCIRE surveillance network and work on avian influenza viruses. Science China Life Sciences, 2017, 60, 1386-1391.	4.9	12
75	Two classes of protective antibodies against Pseudorabies virus variant glycoprotein B: Implications for vaccine design. PLoS Pathogens, 2017, 13, e1006777.	4.7	34
76	Structural basis of nectin-1 recognition by pseudorabies virus glycoprotein D. PLoS Pathogens, 2017, 13, e1006314.	4.7	55
77	Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget, 2017, 8, 67129-67139.	1.8	65
78	Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Science Translational Medicine, 2016, 8, 369ra179.	12.4	194
79	Contribution of intertwined loop to membrane association revealed by Zika virus fullâ€ <del>l</del> ength <scp>NS</scp> 1 structure. EMBO Journal, 2016, 35, 2170-2178.	7.8	126
80	Zika virus NS1 structure reveals diversity of electrostatic surfaces among flaviviruses. Nature Structural and Molecular Biology, 2016, 23, 456-458.	8.2	165
81	Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody. Cell Host and Microbe, 2016, 19, 696-704.	11.0	426
82	In vitro assembly of Ebola virus nucleocapsid-like complex expressed in E. coli. Protein and Cell, 2016, 7, 888-898.	11.0	9
83	Effects of a Single Escape Mutation on T Cell and HIV-1 Co-adaptation. Cell Reports, 2016, 15, 2279-2291.	6.4	19
84	Ribavirin is effective against drug-resistant H7N9 influenza virus infections. Protein and Cell, 2016, 7, 611-614.	11.0	11
85	Potent neutralizing monoclonal antibodies against Ebola virus infection. Scientific Reports, 2016, 6, 25856.	3.3	46
86	Structural and functional analysis of an anchorless fibronectin-binding protein FBPS from Gram-positive bacterium <i>Streptococcus suis</i> . Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13869-13874.	7.1	27
87	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein and Cell, 2016, 7, 866-877.	11.0	44
88	Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. Cell, 2016, 164, 258-268.	28.9	226
89	An Open Receptor-Binding Cavity of Hemagglutinin-Esterase-Fusion Glycoprotein from Newly-Identified Influenza D Virus: Basis for Its Broad Cell Tropism. PLoS Pathogens, 2016, 12, e1005411.	4.7	92
90	A Bat-Derived Putative Cross-Family Recombinant Coronavirus with a Reovirus Gene. PLoS Pathogens, 2016, 12, e1005883.	4.7	92

#	Article	IF	CITATIONS
91	Structural basis for preferential avian receptor binding by the human-infecting H10N8 avian influenza virus. Nature Communications, 2015, 6, 5600.	12.8	28
92	A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Nature Communications, 2015, 6, 7708.	12.8	124
93	Adaptation of avian influenza A (H6N1) virus from avian to human receptorâ€binding preference. EMBO Journal, 2015, 34, 1661-1673.	7.8	44
94	Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People's Republic of China. International Journal of COPD, 2014, 9, 381.	2.3	39
95	Nα-Terminal Acetylation for T Cell Recognition: Molecular Basis of MHC Class I–Restricted Nα-Acetylpeptide Presentation. Journal of Immunology, 2014, 192, 5509-5519.	0.8	14
96	Peptide-dependent Conformational Fluctuation Determines the Stability of the Human Leukocyte Antigen Class I Complex. Journal of Biological Chemistry, 2014, 289, 24680-24690.	3.4	37
97	Bat-derived influenza-like viruses H17N10 and H18N11. Trends in Microbiology, 2014, 22, 183-191.	7.7	270
98	Enabling the 'host jump': structural determinants of receptor-binding specificity in influenza A viruses. Nature Reviews Microbiology, 2014, 12, 822-831.	28.6	213
99	Superimposed Epitopes Restricted by the Same HLA Molecule Drive Distinct HIV-Specific CD8+ T Cell Repertoires. Journal of Immunology, 2014, 193, 77-84.	0.8	15
100	Structures and Receptor Binding of Hemagglutinins from Human-Infecting H7N9 Influenza Viruses. Science, 2013, 342, 243-247.	12.6	237
101	Crystal structures of the two membrane-proximal Ig-like domains (D3D4) of LILRB1/B2: alternative models for their involvement in peptide-HLA binding. Protein and Cell, 2013, 4, 761-770.	11.0	14
102	Structure and receptor-binding properties of an airborne transmissible avian influenza A virus hemagglutinin H5 (VN1203mut). Protein and Cell, 2013, 4, 502-511.	11.0	34
103	Linking innate and adaptive immunity. Science Bulletin, 2012, 57, 4100-4102.	1.7	0
104	Plasticity of human CD8αα binding to peptide–HLA-A*2402. Molecular Immunology, 2011, 48, 2198-2202.	2.2	26
105	Special features of the 2009 pandemic swine-origin influenza A H1N1 hemagglutinin and neuraminidase. Science Bulletin, 2011, 56, 1747-1752.	1.7	14
106	Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein and Cell, 2010, 1, 459-467.	11.0	94
107	Significance of electron microscopic examination in the diagnosis of pulmonary neoplasms. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1995, 7, 61-65.	2.2	0